Thong Dao

TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.

TL;DR: The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy, and the on-treatment virological response was high.

TL;DR: A reduction in critical events, liver-related or not, was confirmed in the CirVir cohort, a prospective study of patients with HCV infection and compensated cirrhosis included in the ANRS cohort who achieved an SVR, to reduce overall mortality and risk of death from liver- related and non-liver-related causes.

TL;DR: The Compassionate Use of Protease Inhibitors in Viral C Cirrhosis (COCIR) study as mentioned in this paper investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis.

TL;DR: In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolia alone, did not result in improved 6-month survival, and the study may have been underpowered to detect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the group receiving pentoxifyinglline.